GLP Review Hub
Clear comparisons. Evidence-first explanations. No hype.
Updated July 16, 2026

Wegovy vs Mounjaro: What Is the Real Difference?

Wegovy and Mounjaro are two of the most heavily discussed treatments on the market. While both influence appetite and digestion, they are built on different active ingredients and target different primary clinical outcomes.

Evidence-based comparison About 10 minutes to read Medically reviewed sources cited
Wegovy versus Mounjaro comparison
Wegovy and Mounjaro utilize different active ingredients to achieve their FDA-approved purposes.
The quick answer: Wegovy contains semaglutide and is specifically approved for chronic weight management in qualifying patients. Mounjaro contains tirzepatide and is primarily approved for blood-sugar control in adults with type 2 diabetes.

Wegovy vs Mounjaro at a Glance

ComparisonWegovy injectionMounjaro injection
Active ingredientSemaglutideTirzepatide
Medication classGLP-1 receptor agonistGLP-1 and GIP receptor agonist
Primary labeled purposeChronic weight management in qualifying patientsBlood-sugar control in adults with type 2 diabetes
Traditional weekly maintenance doseCommonly 1.7 mg or 2.4 mg weeklyRanges from 5 mg up to 15 mg weekly
Weight-loss indicationYes, for qualifying patientsNot the primary FDA-approved indication (see Zepbound)
Common side effectsNausea, diarrhea, vomiting, constipation, abdominal painNausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain
2026 formulation note: While Mounjaro is indicated for type 2 diabetes, its active ingredient tirzepatide is also marketed as Zepbound, which is specifically approved for chronic weight management.

Understanding the Active Ingredients

Wegovy contains semaglutide, a GLP-1 receptor agonist. It helps regulate appetite, signals fullness and slows stomach emptying.

Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors. This dual action affects insulin secretion and appetite regulation.

The most important distinction

A person seeking an FDA-approved treatment specifically for chronic weight management would ordinarily discuss Wegovy. A person with type 2 diabetes needing improved glucose control would ordinarily discuss Mounjaro.

Which One Produces More Weight Loss?

Clinical trial data has often associated tirzepatide with higher average percentages of weight loss than semaglutide, although comparisons between separate trials are imperfect.

Results vary according to dose, duration, starting weight, diet, activity, other conditions and tolerance.

Healthy wellness routine and metabolic support

Dosing: Why the Milligrams Matter

Traditional Wegovy injection schedule

Wegovy is typically started at 0.25 mg weekly and gradually increased to a maintenance dosage of 1.7 mg or 2.4 mg.

Traditional Mounjaro injection schedule

Mounjaro is started at 2.5 mg weekly and may be increased in 2.5 mg increments up to 15 mg weekly.

These milligram amounts cannot be compared directly because the medications contain different active ingredients.

Side Effects

  • Nausea or reduced appetite
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain, bloating or indigestion

Potential serious risks include pancreatitis, gallbladder problems, dehydration-related kidney injury, serious gastrointestinal reactions, allergic reactions and low blood sugar with certain diabetes medicines.

Cost and Insurance Coverage

What a patient pays depends on insurance, diagnosis, prior authorization, employer benefits and manufacturer programs.

Wegovy is commonly evaluated under obesity-treatment criteria, while Mounjaro is commonly evaluated under diabetes criteria.

Who May Be a Better Candidate for Wegovy?

  • Someone meeting the labeled BMI and health-risk criteria.
  • Someone without type 2 diabetes seeking an approved weight-management treatment.
  • Certain adults with established cardiovascular disease who meet the label criteria.

Who May Be a Better Candidate for Mounjaro?

  • An adult with type 2 diabetes needing improved blood-sugar control.
  • Someone whose clinician believes tirzepatide is appropriate and whose plan covers it.

Can You Switch Between Wegovy and Mounjaro?

A clinician may transition a patient between products, but they are not dose-for-dose substitutes.

They should not be taken together unless specifically directed by a qualified prescriber.

Looking beyond prescription GLP-1 medications?

Non-prescription wellness products are not substitutes for Wegovy, Mounjaro, diabetes treatment or professional medical care.

Explore the Orygn Wellness Option

Bottom Line: Wegovy or Mounjaro?

Wegovy is the clearer fit when the goal is FDA-approved chronic weight management in a qualifying patient. Mounjaro is the clearer fit when the primary clinical need is type 2 diabetes management.

Frequently Asked Questions

Can Mounjaro be prescribed for weight loss?

Doctors sometimes prescribe it off-label. Tirzepatide is also sold as Zepbound, which is specifically approved for chronic weight management.

Are Wegovy and Mounjaro the same medication?

No. Wegovy uses semaglutide, while Mounjaro uses tirzepatide.

Which medication leads to more weight loss?

Separate studies often show higher average weight loss with tirzepatide, although individual results vary.

Which one has fewer side effects?

Their digestive side-effect profiles overlap, and tolerability varies.

Can I switch from Wegovy to Mounjaro?

A switch may be possible under a healthcare provider's supervision.

Primary Sources

Medical disclaimer: This page is for general education only and is not medical advice. Affiliate disclosure: GLP Review Hub may earn a commission through featured affiliate links.
← Back to Other Reviews